Cellbox Solutions, a logistics technology company specializing in warm-chain transport for living cells, announced the first closing of its Series A funding round, securing approximately €3.5 million. The round is led by Companisto with participation from existing investors including NRW.BANK. The capital will support international production expansion, global sales growth, and new applications in areas such as cell and gene therapy and in vitro fertilization.
Advancing Warm-Chain Cell Transport
Cellbox develops portable CO₂ incubators designed to transport living cell samples under controlled physiological conditions. The patented warm-chain technology maintains stable environments for up to 48 hours, preserving cell viability and functionality during shipment. The systems comply with IATA air transport regulations and are already used by more than 300 customers worldwide across pharmaceutical companies, biotechnology firms, research institutions and universities.
Strengthening Leadership for Global Growth
As part of the company’s next growth phase, Dr. Bernd Muehlenweg has joined Cellbox as Chief Business Officer and Chief Financial Officer. With more than two decades of experience in the life sciences sector, Dr. Muehlenweg previously served as Senior Vice President and Global Head of Business Development, Cell Therapy at Evotec.
“Cellbox™ is setting a new benchmark in the transportation of living cells. By enabling safe, controlled, and reproducible transport under physiological conditions, we address a critical bottleneck in the life sciences industry. The investment round marks an important milestone in expanding our international footprint and establishing Cellbox™ as a global infrastructure standard for living cell shipment and warm-chain logistics. Our patented platform and strong regulatory positioning provide an excellent foundation for global scale-up across multiple life sciences applications, including the rapidly growing field of cell and gene therapies. I look forward to further strengthening our commercial operations, expanding our service portfolio, and building the organizational structures required to support the next phase of international growth,” commented Dr. Bernd Muehlenweg, CBO & CFO of Cellbox Solutions GmbH.
Scaling Infrastructure for Advanced Therapies
The funding supports the expansion of Cellbox’s technology platform as demand grows for reliable transport of sensitive biological materials. Warm-chain logistics is increasingly important as advanced therapies move from research into clinical and commercial deployment.
“Our vision is to redefine how living cells are transported globally. With the continued support of our investors and the strengthening of our leadership team with a highly experienced executive, we are building the foundation for long-term international growth and expanding the reach of warm-chain logistics across clinical and research applications. We are convinced that reliable live-cell transport will become an essential component of the global life sciences value chain,” concluded Prof. Dr. Kathrin Adlkofer, Founder and CEO of Cellbox™.